QPS is well known as a leading CRO for CNS drug development. The availability of the most predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes turn QPS into the first choice for most research needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of AD, PD, HD and other neurodegenerative diseases.

QPS is known for
  • Customers contentedness being our absolute priority
  • High quality studies on GLP level
  • Every study being custom-built
  • Clients timeline being QPS´ timeline
  • Being scientifically up to date
  • Being AAALAC accredited

Neuropharmacology Leadership Team

Birgit Hutter-Pair
Birgit Hutter-Paier
Director Neuropharmacology Department
Vera Niederkofler
Vera Niederkofler
Head of In Vivo Research
Joerg Neddens
Joerg Neddens
Head of Histology

Tina Loeffler
Tina Loeffler
Head of In Vitro Research
Sara Peinkiher
Sara Peinkiher
Head of Animal Facility
Manuela Prokesch
Manuela Prokesch
Director of Quality Assurance

In Vitro

In Vitro Testing at QPS

QPS provides numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.

In our cell culture systems we mimic disease related lesions for Alzheimer's, Parkinson's and Huntington's Disease, Ischemia and other neuro-degenerative events. In addition, we perform assays for drug safety and have several systems available to test secretase modulators and inhibitors.

Send us a request to develop a straightforward strategy to support your development program.

Animal Models

QPS is the premier provider for services with transgenic animals. The enterprise gained experiences in generating, characterizing and maintenance of transgenic disease models and using them for drug testing projects since more than ten years.

The mouse and rat models available for drug development in Alzheimer’s, Parkinson’s and Huntington’s disease allow the quantitative evaluation of compound interactions with Amyloid, Tau, inflammation related markers, mitochondrial deficiency and other pathologies.

We are happy to receive any information request to elaborate the most efficient way, including behavioral, immunohistochemical, biochemical and molecular biological techniques, for the support of your drug development approach.


Behavioral Testing

Several customized behavioral tests are offered to phenotype mouse and rat models and evaluate effects of compounds in different in vivo models.

New behavioral tests are continuously developed and validated.


QPS is specialized in qualitative and quantitative brain research related to Alzheimer’s and Parkinson’s diseases (inflammation, plaques, tangles, …), but also offers investigations to other subjects of interest, e.g. Huntington’s disease, amyotrophic lateral sclerosis (ALS), stroke, microbleeding, spinal cord myelination and remyelination, schizophrenia (Neuregulin-ErbB4 pathway), subtypes of GABAergic interneurons (relevant for epilepsy and schizophrenia), etc.

CNS Biomarker

CNS Biomarker Laboratories

Due to significant investments in highly trained staff and equipment, QPS is capable to provide a state of the art research environment for testing and evaluating new potential treatment approaches. To ensure outstanding quality research with the highest level of control, QPS introduced a LIMS. In addition, biological safety is fundamental in various drug development programs. QPS maintains laboratories under S2 conditions.

The CNS Biomarker Laboratories are located in the same building as the animal facility, the clinical trial department as well as the quality assurance unit. Thereby, QPS ensures the best overview over the complete drug development performed within our company.


20 years in pharma R&D navigation